Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
The Phase 3 MajesTEC 3 trial showed that teclistamab plus daratumumab reduced the risk of progression or death by 83% and ...
Teclistamab-cqyv plus subcutaneous daratumumab significantly improved OS and PFS in relapsed/refractory multiple myeloma compared to standard regimens, reducing death risk by 54%. The combination ...
MedPage Today on MSN
Bispecific trial in myeloma sparks talks of 'functional cure'
The complete response or better rate was 81.1% with the combination versus 31.1% in the control arm, while patients treated with the combination were more likely to test negative for minimal residual ...
The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...
Johnson & Johnson’s Tecvayli (teclistamab-cqyv), used in combination with daratumumab to treat relapsed or refractory multiple myeloma, has received FDA’s latest national priority voucher, becoming ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback